Liquidia stock holds Buy rating at BofA on competitive edge
#Liquidia #BofA #Buy rating #stock #competitive edge #analyst #pharmaceutical
📌 Key Takeaways
- BofA maintains a Buy rating on Liquidia stock.
- The rating is based on Liquidia's competitive edge.
- The article does not specify the nature of the competitive edge.
- The news is a brief analyst update on the stock.
🏷️ Themes
Stock Rating, Biotechnology
📚 Related People & Topics
Bank of America
American multinational banking and financial services corporation
The Bank of America Corporation (Bank of America; often abbreviated BAC or BofA) is an American multinational investment bank and financial services holding company headquartered at the Bank of America Corporate Center in Charlotte, North Carolina, with investment banking and auxiliary headquarters ...
Entity Intersection Graph
Connections for Bank of America:
🌐
SEC filing
2 shared
🌐
Artificial intelligence
2 shared
🌐
Tesla
1 shared
🌐
Robotaxi
1 shared
🏢
Ultragenyx
1 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump replaces Homeland Security chief Kristi Noem Oil extends weekly gains as Iran conflict rages on, with crude surging around 20% Gold prices dip as stronger dollar weighs; Iran conflict remains in focus Dollar resumes climb on safe haven demand as Iran conflict rages on (South Africa Philippines Nigeria) Liquidia stock holds Buy rating at BofA on competitive edge By Analyst Ratings Published 03/05/2026, 03:47 PM Liquidia stock holds Buy rating at BofA on competitive edge 0 LQDA 0.47% Investing.com - BofA Securities reiterated a Buy rating and $44.00 price target on Liquidia Technologies stock (NASDAQ:LQDA) on Thursday. The stock has delivered a remarkable 121% return over the past year and currently trades at $34.07, up nearly 12% in the last week alone. The firm’s analyst Greg Harrison maintained the rating following management commentary on competitive developments in the prostacyclin treatment space. Liquidia management said it expects competitor United Therapeutics’ Phase 3 ralinepag oral therapy to compete primarily against other oral agents like Uptravi due to similar profiles and gastrointestinal side effects with limited symptomatic improvement. The company questioned whether patients would accept gastrointestinal side effects versus better-tolerated inhalers that can be dosed up. Regarding United Therapeutics’ development-stage soft mist inhaler, Liquidia questioned claims of 90% cough adverse event reduction, noting the data has not been published. The company also raised concerns about whether healthy volunteer data would translate to disease patients predisposed to coughing. Management said patent literature suggests the soft mist inhaler’s particle size may limit its ability to bypass upper airway irritation that causes severe cough adverse events.According to InvestingPro , which offers 12 additional exclusive tips for LQDA, analysts anticipate continued sales growth despite the company not ...
Read full article at source